Drug intelligence / Profile preview

LWEL-2103

Development stage: Preclinical
Lead developer: Luckwel Pharmaceuticals

Overview

LWEL-2103 (SAMHOVIR) is a preclinical drug candidate being developed by Luckwel Pharmaceuticals for the treatment of COVID-19. It is categorized under the company's infectious disease programs. As of the current pipeline information, the specific molecular target and modality (e.g., small molecule, antibody) have not been publicly disclosed. The program is currently in the preclinical stage of development with global rights held by Luckwel Pharmaceuticals.

Other names: SAMHOVIR

Beyond the preview

Go deeper on LWEL-2103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LWEL-2103.

Explore the full profile